Nimodipina Pensa (Nimodipine)

Nimodipine, the active ingredient in Nimodipina Pensa, is a calcium channel blocker (dihydropyridine) presented as an oral formulation for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients. GNH USA supplies Nimodipina Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine acts on cerebral vascular smooth muscle to reduce vasospasm after hemorrhagic events. - Subarachnoid hemorrhage: prevention of cerebral vasospasm after aneurysmal bleed - Cerebral vasospasm: reduction of vessel constriction to improve cerebral blood flow - Neurological complications post‑SAH: support of recovery by maintaining adequate perfusion

Nimodipine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity - Hypotension: transient blood pressure drop - Nausea: occasional gastrointestinal upset - Flushing: warmth and redness of skin - Dizziness: sensation of light‑headedness - Tachycardia: increased heart rate

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring medical attention - Myocardial infarction: rare cardiac ischemic events - Hepatic dysfunction: abnormal liver enzymes or hepatitis - Allergic reactions: rash, pruritus, or anaphylaxis - Blood dyscrasias: neutropenia or thrombocytopenia

Before prescribing Nimodipina Pensa, clinicians should consider several safety aspects. - Blood pressure monitoring: check for hypotension, especially after initiation - Hepatic impairment: adjust use in patients with severe liver disease - Pregnancy: category C, use only if benefit outweighs risk - Elderly patients: start at lower dose and monitor closely - Concomitant antihypertensives: avoid excessive blood pressure lowering - Store below 25°C: keep in the original pack, protect from moisture.

Nimodipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nimodipine levels - Potent vasodilators (e.g., nitroglycerin): risk of severe hypotension - Other calcium‑channel blockers: additive cardiovascular effects

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents (beta‑blockers, ACE inhibitors): monitor blood pressure - CYP3A4 substrates (e.g., statins): possible increased exposure - Diuretics: watch for electrolyte disturbances - NSAIDs: may blunt antihypertensive effect